SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - AMAM, TGAN, CSTR, THRX
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - AMAM, TGAN, CSTR, THRX
PR Newswire
NEW YORK, Feb. 5, 2024
NEW YORK, Feb. 5, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are now investigating:
- Ambrx Biopharma, Inc. (Nasdaq: AMAM), relating to its proposed sale to Johnson & Johnson. Under the terms of the agreement, AMAM shareholders will receive $28.00 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/ambrx-biopharma-inc. It is free and there is no cost or obligation to you.
- Transphorm, Inc. (Nasdaq: TGAN), relating to its proposed sale to Renesas Electronics Corp. Under the terms of the agreement, TGAN shareholders will receive $5.10 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/transphorm-inc. It is free and there is no cost or obligation to you.
- CapStar Financial Holdings, Inc. (Nasdaq: CSTR), relating to its proposed sale to Old National Bancorp. Under the terms of the agreement, CSTR shareholders will receive 1.155 shares of Old National per share they own. Click here for more information: https://www.monteverdelaw.com/case/capstar-financial-holdings-inc. It is free and there is no cost or obligation to you.
- Theseus Pharmaceuticals, Inc. (Nasdaq: THRX), relating to its proposed sale to Concentra Biosciences, LLC. Under the terms of the agreement, THRX shareholders are expected to receive between $3.90 and $4.05 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/theseus-pharmaceuticals-inc. It is free and there is no cost or obligation to you.
Before you hire a law firm, you should talk to a lawyer and ask:
- Do you recover money for shareholders?
- Do you litigate and go to Court?
- Do you even go to the office and wear a suit?
About Monteverde & Associates PC
Juan Monteverde is a Spaniard and a born fighter. Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court.
No company, director or officer is above the law. If you own common stock in any of the above listed companies and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.
Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341
Attorney Advertising. (C) 2024 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-investigation-the-ma-class-action-firm-continues-investigating-the-merger--amam-tgan-cstr-thrx-302053922.html
SOURCE Monteverde & Associates PC
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth